<DOC>
	<DOCNO>NCT01698866</DOCNO>
	<brief_summary>The purpose study assess seroconversion rate cellular immune response vaccination hepatitis B virus patient lymphoproliferative syndrome like chronic lymphocytic leukemia stade A follicular lymphoma without treatment criterion .</brief_summary>
	<brief_title>Low Grade Lymphoma</brief_title>
	<detailed_description>Rituximab human-mouse chimeric monoclonal antibody target B-cell CD20 . It indispensible drug treatment B-cell lymphoproliferative syndrome induced immunosuppression . So , infectious complication increase . Reactivation hepatitis B virus one complication lead asymptomatic hepatitis death . Prevention hepatitis B reactivation recommend like use nucleoside analog patient chronic hepatitis B occult hepatitis vaccination virus seronegative patient . The publish data efficacy hepatitis b vaccination onco-haematology rare . therefore , carry prospective study ass efficacy hepatitis B vaccination patient lymphoproliferative disorder .</detailed_description>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age â‰¥ 18 year . Lymphoproliferative indolent type stage A CLL follicular lymphoma low tumor burden No indication chemotherapy seven month vaccination protocol . HBV serology negative HBsAg / Ab HBs / HBc Ab . No history vaccination hepatitis B . Indication immediate chemotherapy . At least one HBV positive serologic marker . History vaccination HBV . Known neurodegenerative disease . Pregnancy . Febrile infection untreated . Known allergy vaccine component .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Low grade lymphoma</keyword>
	<keyword>follicular lymphoma</keyword>
	<keyword>indolent lymphoproliferative disorder</keyword>
	<keyword>Vaccin GenHevac B Pasteur</keyword>
</DOC>